Biogenerics, World Market

Worldwide interest in biogenerics or biosimilars is gaining momentum. Since Kalorama Information last visited the market for synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies four years ago, there has been much more worldwide involvement in the development of the biogeneric arena.

The biological drug market is at a crossroad. Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. This opens up the market currently worth $40 billion and growing at over 20% per year if the regulatory hurdles can be overcome.

Kalorama Information's survey includes as part of its market analysis a breakdown of generic replacements for:

* Drugs with Active patents

* Drugs with Expired patents

with this geographic breakdown:

* World

* US

* non-US

In addition to market information, this report includes:

* Complete Overview

* Patent dates for Major Biopharmaceuticals

* Issues and Trends in the Industry

* Scientific Differences Between Biopharmaceuticals and Biogenerics

* Key Regulations Affecting this Market

* Company Profiles

As part of Kalorama Information's trusted information gathering process, this report is the result of both primary and secondary research. In addition to exhaustive research, Key executives at biogeneric companies were consulted to uncover key trends and develop models.

Apr 1, 2008 153 Pages
Table of Contents

Price